Global Companion Diagnostics Partnering Terms and Agreements 2010-2020

$3,495.00

The Global Companion Diagnostics Partnering Terms and Agreements 2010-2020 report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
May 2020
Number of pages
300+
Product type
Research report
Available formats
PDF document
Report edition
3
SKU
CP2106

The Global Companion Diagnostics Partnering Terms and Agreements 2010-2020 report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

 

  • Trends in companion diagnostics partnering deals
  • Companion diagnostics partnering agreement structure
  • Companion diagnostics partnering contract documents
  • Top companion diagnostics deals by value
  • Most active companion diagnostics dealmakers

 

The report provides a detailed understanding and analysis of how and why companies enter Companion Diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

 

This report provides details of the latest Companion Diagnostics agreements announced in the life sciences since 2010.

 

The report takes the reader through a comprehensive review Companion Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Companion Diagnostics partnering deals.

 

The report presents financial deal term values for Companion Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

 

The middle section of the report explores the leading dealmakers in the Companion Diagnostics partnering field; both the leading deal values and most active Companion Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

 

One of the key highlights of the report is that over 450 online deal records of actual Companion Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

 

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

 

The initial chapters of this report provide an orientation of Companion Diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Companion Diagnostics dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

 

Chapter 3 provides a review of the leading Companion Diagnostics deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Companion Diagnostics dealmaking with a brief summary followed by a comprehensive listing of Companion Diagnostics deals announded by that company, as well as contract documents, where available.

 

Chapter 5 provides a comprehensive and detailed review of Companion Diagnostics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive and detailed review of Companion Diagnostics partnering deals signed and announced since Jan 2010. The chapter is organized by specific Companion Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

 

A comprehensive series of appendices is provided organized by Companion Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in Companion Diagnostics partnering and dealmaking since 2010.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Companion Diagnostics technologies and products.

 

Key benefits

 

Global Companion Diagnostics Partnering Terms and Agreements 2010-2020 provides the reader with the following key benefits:

 

  • In-depth understanding of Companion Diagnostics deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Companion Diagnostics agreements with numerous real life case studies
  • Detailed access to actual Companion Diagnostics contracts entered into by leading biopharma companies
  • Identify most active Companion Diagnostics dealmakers since 2010
  • Insight into terms included in a Companion Diagnostics partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

 

Report scope

 

Global Companion Diagnostics Partnering Terms and Agreements 2010-2020 is intended to provide the reader with an in-depth understanding and access to Companion Diagnostics trends and structure of deals entered into by leading companies worldwide.

 

Companion Diagnostics Partnering Terms and Agreements includes:

 

  • Trends in Companion Diagnostics dealmaking in the biopharma industry since 2010
  • Analysis of Companion Diagnostics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Companion Diagnostics deals
  • Access to Companion Diagnostics contract documents
  • Leading Companion Diagnostics deals by value since 2010
  • Most active Companion Diagnostics dealmakers since 2010

 

In Global Companion Diagnostics Partnering Terms and Agreements 2010-2020, the available deals are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The Global Companion Diagnostics Partnering Terms and Agreements 2010-2020 report provides comprehensive access to available deals and contract documents for over 450 Companion Diagnostics deals.

 

Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Companion Diagnostics Partnering Terms and Agreements 2010-2020 provides the reader with the following key benefits:

 

  • In-depth understanding of Companion Diagnostics deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Companion Diagnostics agreements with numerous real life case studies
  • Detailed access to actual Companion Diagnostics contracts entered into by leading biopharma companies
  • Identify most active Companion Diagnostics dealmakers since 2010
  • Insight into terms included in a Companion Diagnostics partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in Companion Diagnostics dealmaking

 

2.1. Introduction

2.2. Companion Diagnostics partnering over the years

2.3. Most active Companion Diagnostics dealmakers

2.4. Companion Diagnostics partnering by deal type

2.5. Companion Diagnostics partnering by therapy area

2.6. Deal terms for Companion Diagnostics partnering

2.6.1 Companion Diagnostics partnering headline values

2.6.2 Companion Diagnostics deal upfront payments

2.6.3 Companion Diagnostics deal milestone payments

2.6.4 Companion Diagnostics royalty rates

 

Chapter 3 – Leading Companion Diagnostics deals

 

3.1. Introduction

3.2. Top Companion Diagnostics deals by value

 

Chapter 4 – Most active Companion Diagnostics dealmakers

 

4.1. Introduction

4.2. Most active Companion Diagnostics dealmakers

4.3. Most active Companion Diagnostics partnering company profiles

 

Chapter 5 – Companion Diagnostics contracts dealmaking directory

 

5.1. Introduction

5.2. Companion Diagnostics contracts dealmaking directory

 

Chapter 6 – Companion Diagnostics dealmaking by technology type

 

Chapter 7 – Partnering resource center

 

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking

 

Appendices

 

Appendix 1 – Companion Diagnostics deals by company A-Z

 

Appendix 2 – Companion Diagnostics deals by stage of development

 

Discovery

Preclinical

Phase I

Phase II

Phase III

Regulatory

Marketed

Formulation

 

Appendix 3 – Companion Diagnostics deals by deal type

 

Asset purchase

Assignment

Bigpharma outlicensing

Co-development

Collaborative R&D

Co-market

Co-promotion

CRADA

Cross-licensing

Development

Distribution

Equity purchase

Evaluation        

Grant

Joint venture

Licensing

Litigation

Manufacturing

Marketing

Material transfer

Option

Promotion

Research

Settlement

Spin out

Sub-license

Supply

Technology transfer

Termination

Warranty

 

Appendix 4 – Companion Diagnostics deals by therapy area

 

Appendix 5 –Deal type definitions

 

About Wildwood Ventures

 

Current Partnering

Current Agreements

Recent report titles from Current Partnering

 

Table of figures

 

Figure 1: Companion Diagnostics partnering since 2010

Figure 2: Active Companion Diagnostics dealmaking activity since 2010

Figure 3: Companion Diagnostics partnering by deal type since 2010

Figure 4: Companion Diagnostics partnering by disease type since 2010

Figure 5: Companion Diagnostics deals with a headline value

Figure 6: Companion Diagnostics deals with an upfront value

Figure 7: Companion Diagnostics deals with a milestone value

Figure 8: Companion Diagnostics deals with a royalty rate value

Figure 9: Top Companion Diagnostics deals by value since 2010

Figure 10: Most active Companion Diagnostics dealmakers since 2010

Figure 11: Online partnering resources

Figure 12: Forthcoming partnering events

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

20/20 GeneSystems, AB-Biotics, Abbott Laboratories, Abbott Molecular, Abbvie, Abcam, AB Science, AccuGenomics, Achaogen, Acobiom, ADC Therapeutics, Advanced Biological Laboratories, Advanced Cell Diagnostics, Advanced Nuclear Medicine Ingredients, Advaxis, Aelan Cell Technologies, Aerocrine, AEterna Zentaris, Affymetrix, Agilent Technologies, Agios Pharmaceuticals, Akili Interactive Labs, Akoya Biosciences, Albert Einstein College of Medicine, Algeta, Almac Diagnostics, Almac Group, AltheaDX, Amarantus BioSciences, Ambit Biosciences, Amgen, Amoy Diagnostics, AmpliPhi Biosciences, AmpTec, Analytics Engines, Angle, Apogenix, ArcherDX, Ariad Pharmaceuticals, ARK Diagnostics, Arno Therapeutics (inactive since 2017), Array Biopharma, AssureRx Health, Astellas Pharma, Astellas Pharma US, Astex Pharmaceuticals, AstraZeneca, Astrimmune, Asuragen, Atherotech, Atossa Genetics, Aushon BioSystems, Australian Research Council, AVEO Oncology, Avila Therapeutics, Banner Sun Health Research Institute (BSHRI), Baxter International, Bayer, Bayer Healthcare, BC Cancer Agency, Beckman Coulter, Becton Dickinson, BeiGene, Beijing InnoCare Pharma, BG Medicine, BioBay, Biocare Medical, Biocartis, Biocept, BioChain, Biodel, Biodesix, Biogen, Biognosys, BioImagene, BioMarin Pharmaceutical, BioMarker Strategies, Biomerica, bioMerieux, Biomoda, Biovica, Bliss Biopharmaceutical, Blueprint Medicines, Boehringer Ingelheim, Bonnie J. Addario Lung Cancer Foundation, Bpifrance, Bristol-Myers Squibb, Bristol-Myers Squibb Pakistan, California NanoSystems Institute (CNSI), Cambridge Biomedical, Canary Foundation, CANbridge Life Sciences, Cancer Genetics, Cancer Research Technology, Cancer Research UK, Cancer Treatment Centers of America, Carena, Caris Life Sciences, Case Western Reserve University, CDx Diagnostics, Cedars-Sinai Medical Center, Celgene, Celladon, Celldex Therapeutics, Cellgen Diagnostics, Cell Signaling Technology, Centre for Imaging Technology Commercialization, Centre National de la Recherche Scientifique, Cephalon, Cepheid, Cernostics, CHDI Foundation, Chembio Diagnostics, Chronix Biomedical, Chugai Pharmaceutical, Ci-Co Healthcare, Clarient, Clarity Pharmaceuticals, Clavis Pharma, Clevexel Pharma, Clinical Genomics, Clinical Reference Laboratory, Cloud Pharmaceuticals, Clovis Oncology, Columbia University, Columbia University Medical Center, CombiMatrix, Commercialisation Australia, CompanDX, Companion Dx Reference Lab, Companion Medical, Compendia Bioscience, Core Diagnostics India, Corgenix Medical, Cornell University, Covance, CStone Pharmaceuticals, Cylene Pharma, Cynvenio, Daiichi Sankyo, Dako, Dalton Pharma Services, Dana-Farber Cancer Institute, David H. Murdock Research Institute, Debiopharm, Definiens, Department of Defense, DermTech, DiagnoCure, DiamiR, Diaxonhit, Dimerix Biosciences, DxS, Eisai, Eli Lilly, Emory University, Empire Genomics, Endocyte, Enlyten Medical Technologies, Enterome Bioscience, Enzo Biochem, Epic Sciences, Epigenomics, Epitomics, Epizyme, Erytech, Eureka Eurostars, Eurofins Genomics, European Union Regional Development Fund, Eurotrans-Bio, Eutropics Pharmaceuticals, Evotec, Exact Sciences, EXINI Diagnostics, ExonHit Therapeutics, Exosome Diagnostics, Federal Ministry of Education and Research (BMBF), FEI, Ferring Pharmaceuticals, Fibrocell Science, Five Prime Therapeutics, Flagship Biosciences, Foundation Medicine, Fox Chase Cancer Center, Freenome, French National Research Agency, Fujirebio Diagnostics, Fusion Antibodies, Galena Biopharma, Galmed Pharmaceuticals, GE Healthcare, Geisinger Health System, Genentech, Generex Biotechnology, Genetic Technologies, Genetron Health, Genmab, Genome Diagnostics, GenomeDx, Genomeon, Genomic Health, Genomic Testing Cooperative, Genoptix, Genzyme, German Cancer Research Center, GI Pathology, GlaxoSmithKline, GlaxoSmithKline Biologicals, Glythera, Golden Helix, Guardant Health, HalioDx, Halozyme Therapeutics, Health Diagnostics Laboratory, Health Discovery, HistologiX, Hoffmann La Roche, Horizon, Horizon Discovery, Hospices Civils de Lyon, Hospital del Mar, HTG Molecular Diagnostics, Hybrigenics, Icon, IDbyDNA, Idera Pharmaceuticals, IDEXX Laboratories, Illumina, ImaginAb, Imanis Life Sciences, IMIDomics, ImmunID Technologies, ImmunoCellular Therapeutics, ImmunoGen, ImmusanT, IncellDx, Incyte, Informed Data Systems, Inform Genomics, Innovate UK, Inotrem, Inova Diagnostics, Inovio Pharmaceuticals, Inserm Transfert, Insight Genetics, IntegraGen, Integrated Biobank of Luxembourg, International Cancer Genome Consortium, Intezyne, Invivis Pharmaceuticals, InVivoScribe, Ionis Pharmaceuticals, Ion Torrent, Ipsen, Ipsogen, IRCCS, Ironwood Pharmaceuticals, IRX Therapeutics, Janssen Biotech, Janssen Pharmaceutica NV, Janssen Research & Development, Jiangsu Hengrui Medicine, Johns Hopkins University, Johnson & Johnson Innovation, Kalgene Pharmaceuticals, KineMed, Kreatech, KSB Diagnostics, Lab21, Laboratory Corporation of America, Lehigh Valley Health Network, Leica Biosystems, Leica Microsystems, Les Laboratoires Servier, Life Technologies, Life Technologies Corporation, Locus Biosciences, London Genetics, Loxo Oncology, Luminex, Lumiphore, LUNGevity Foundation, Luye Pharma Group, Macquarie University, Macrogenics, Massachusetts General Hospital, Massachusetts Institute of Technology, Max Planck Institute for Infection Biology, Mayo Clinic, McKesson, MD Anderson Cancer Center, MDxHealth, Med BioGene, Medco Health Solutions, Medical Prognosis Institute, Medivation, Memorial Sloan Kettering Cancer Center, Merck and Co, Merck KGaA, Merck Serono, Merck Sharpe & Dohme, Merrimack Pharmaceuticals, Merus, Metamark Genetics, MetaStat, Michael J Fox Foundation, Mikrogen, Millennium, Millennium Medical Devices, Miragen Therapeutics, Mirati Therapeutics, MolecularMD, Montefiore Medical Center, Morphotek, MWI Veterinary Supply, Myriad Genetics, NanoString Technologies, National Cancer Institute, National Center for Drug Screening, National Heart, Lung and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, National Science Foundation, Nemucore Medical Innovations, Neogenix Oncology, Neogenomics, Networking Biomedical Research Centre in Liver and Digestive Diseases (CIBEREHD), NeuroMetrix, Newcastle University, New Liberty Proteomics, New York University, Nexpep, Nicholas Conor Institute for Pediatric Cancer Research, Nihon Medi-Physics, Nipro Diagnostics, NMI TT Pharmaservices, Nodality, North Carolina State University, Novartis, NovioGendix, Novogene, Nuclea Biotechnologies, NuSirt, OcellO, On-Q-ity, Oncology Venture, OncoMed Pharmaceuticals, One Way Liver Genomics (OWL), Ono Pharmaceutical, Ontario Cancer Biomarker Network, Ontario Institute for Cancer Research, OPKO Health, Oridis Biomarkers, Ortho-Clinical Diagnostics, OSEO, OSI Pharmaceuticals, Oxford BioMedica, Oxford Gene Technology, OxOnc Development, Paradigm, Patrys, Peking University Cancer Hospital, Penn State Hershey, PerkinElmer, Personal Genome Diagnostics, Personalis, Pfizer, Pharmacyclics, PharmaMar, Photocure ASA, Pierre Fabre, Piramal Imaging, Precision for Medicine, Precision Therapeutics, Primeradx, Profusa, Prometheus Laboratories, Protagen, Proteomics International, Puma Biotechnology, Pure MHC, Q2 Solutions, Q BioMed, QED Therapeutics, Qiagen, QIAGEN (Suzhou) Translational Medicine Center, Quest Diagnostics, Quintiles, R-Biopharm, RedHill Biopharma, Regulus Therapeutics, ResearchDx, Research Institute of the Hospital Universitari Vall d'Hebron, Resolution Bioscience, Respira Health, Roche, Roche Diagnostics, Roche Molecular Systems, Rush University Medical Center, Saladax Biomedical, Salix Pharmaceuticals, Samsung Medical Center, Sanofi, San Raffaele Scientific Institute, Scancell, Seattle Genetics, Seegene, Sengenics, Sentinel Oncology, Seoul National University, Serametrix, Shanghai Pharmaceuticals Holdings, Shenzhen Chipscreen Biosciences, Shuwen Biotech, Siemens Healthcare, Siemens Healthcare Diagnostics, Singapore Radiopharmaceuticals, Singulex, Sirius Genomics, Small Business Innovation Research, Smart Personalized Medicine, Source Bioscience, Spectral Medical, Spectrum Pharmaceuticals, Splicos, SRL, Stallergenes, Strata Oncology, STRATIFYER Molecular Pathology, Summit Pharmaceuticals, Sunnybrook Health Sciences Centre, SuperNova Diagnostics, Syapse, Syndax Pharmaceuticals, Synthon, Sysmex Inostics, Takeda Pharmaceutical, Tasly Pharmaceuticals, TcLand Expression, Technology Strategy Board (UK), Technology Transfer Accelerator, Telix Pharmaceuticals, Tesaro, The Fleury Group, The Parker Institute For Cancer Immunotherapy, Theradiag, Thermo Fisher Scientific, Threshold Pharmaceuticals, Tocagen, Tokai Pharmaceuticals, Tolero Pharmaceuticals, TP Therapeutics, TRACON Pharmaceuticals, Transgene, Transgenomic, Translational Drug Development, uBiome, UCB, Unilabs, University College London, University Health Network, University of Barcelona, University of Bonn, University of California, San Diego, University of California Los Angeles, University of Central Florida Research Foundation, University of Colorado Denver, University of Kansas, University of Minnesota, University of North Texas Health Science Center, University of Pennsylvania, University of Pennsylvania School of Veterinary Medicine, University of Pittsburgh Cancer Institute, University of Tokyo, University of Washington, USBiomarkers, ValiRx, Van Andel Institute, Vector Oncology, Vela Diagnostics, Ventana Medical Systems, Veracyte, Verastem, Veridex, Vertex Pharmaceuticals, ViiV Healthcare, ViroMed, Virovek, VuCOMP, Vyriad, Wake Forest University School of Medicine, WAVE Life Sciences, Whitehead Institute, WuXi NextCODE Genomics, XDx, Xenon Pharmaceuticals, Yale University, Zinfandel Pharmaceuticals, Zora Biosciences

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.

We found other products you might like!